Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00379470
Other study ID # EF-11
Secondary ID
Status Completed
Phase Phase 3
First received September 20, 2006
Last updated April 29, 2012
Start date September 2006
Est. completion date January 2011

Study information

Verified date April 2012
Source NovoCure Ltd.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields (termed TTFields).


Description:

PAST CLINICAL EXPERIENCE:

The effect of the electric fields generated by the NovoTTF-100A device (TTFields) has been tested in two pilot trials in humans. The data from these trials suggest NovoTTF-100A may improve time to disease progression and overall survival of recurrent GBM patients. Although the number of patients in the pilot trials is small, The FDA has determined that the data gathered so far warrant testing of NovoTTF-100A treatment as a possible therapy for patients with recurrent GBM.

DESCRIPTION OF THE TRIAL:

Patients with GBM whose disease has recurred or progressed despite standard treatment (Surgery, radiation therapy, Temozolomide treatment) and meet all of the requirements for participation in the study will be randomly assigned to one of two groups:

1. Treatment with the NovoTTF-100A device, or

2. Treatment with the best standard of care practiced at each of the participating centers.

If assigned to the best standard of care group, patients will receive a chemotherapeutic agent chosen based on their prior treatments and the standard of care practiced at each treating center.

If assigned to the NovoTTF-100A group, the patients will be treated continuously for as long as their disease is stable or regressing. NovoTTF-100A treatment will consist of wearing four electrically insulated electrodes on the head. Electrode placement will require shaving of the scalp before treatment. After an initial short hospitalization (24 hours) patients will be released to continue treatment at home where they can maintain their regular daily routine.

During the trial, regardless of whether assigned to the NovoTTF-100A treatment group or the best standard of care group, patients will need to return once every month the hospital outpatient clinics where they will be examined by a physician and undergo routine laboratory examinations. These routine visits will continue for as long as the patient's disease is not progressing. After progression, if such occurs, patients will need to return once per month for two more months to the outpatient clinic for similar follow up examinations.

During the visits to the clinic patients will be examined physically and neurologically. Additionally, routine blood tests and ECG will be performed. A routine MRI of the head will be performed at baseline and after 2, 4 and 6 months. After this follow up plan, patients will be contacted once per month by telephone to answer basic questions about their health status.

SCIENTIFIC BACKGROUND:

Electric fields exert forces on electric charges similar to the way a magnet exerts forces on metallic particles within a magnetic field. These forces cause movement and rotation of electrically charged biological building blocks, much like the alignment of metallic particles seen along the lines of force radiating outwards from a magnet.

Electric fields can also cause muscles to twitch and if strong enough may heat tissues. TTFields are alternating electric fields of low intensity. This means that they change their direction repetitively many times a second. Since they change direction very rapidly (200 thousand times a second), they do not cause muscles to twitch, nor do they have any effects on other electrically activated tissues in the body (brain, nerves and heart). Since the intensities of TTFields in the body are very low, they do not cause heating.

The breakthrough finding made by NovoCure was that finely tuned alternating fields of very low intensity, now termed TTFields (Tumor Treating Fields), cause a significant slowing in the growth of cancer cells. Due to the unique geometric shape of cancer cells when they are multiplying, TTFields cause the building blocks of these cells to move and pile up in such a way that the cells physically explode. In addition, cancer cells also contain miniature building blocks which act as tiny motors in moving essential parts of the cells from place to place. TTFields cause these tiny motors to fall apart since they have a special type of electric charge.

As a result of these two effects, cancer tumor growth is slowed and can even reverse after continuous exposure to TTFields.

Other cells in the body (normal healthy tissues) are affected much less than cancer cells since they multiply at a much slower rate if at all. In addition TTFields can be directed to a certain part of the body, leaving sensitive areas out of their reach.

In conclusion, TTField hold the promise of serving as a brand new cancer treatment with very few side effects and promising affectivity in slowing or reversing this disease.


Recruitment information / eligibility

Status Completed
Enrollment 236
Est. completion date January 2011
Est. primary completion date November 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pathological evidence of GBM using WHO classification criteria.

- > 18 years of age.

- Not a candidate for further radiotherapy or additional resection of residual tumor.

- Patients with disease progression (by Macdonald criteria i.e., > 25% or new lesion) documented by CT or MRI within 4 weeks prior to enrollment

- Karnofsky scale = 70

- Life expectancy at least 3 months

- Participants of childbearing age must use effective contraception.

- All patients must sign written informed consent.

Exclusion Criteria:

- Actively participating in another clinical treatment trial

- Within 4 weeks from surgery for recurrence

- Within 4 weeks from any prior chemotherapy.

- Within 4 weeks from radiation therapy

- Pregnant

- Significant co-morbidities (within 4 weeks prior to enrollment):

1. Significant liver function impairment - AST or ALT > 3 times the upper limit of normal

2. Total bilirubin > upper limit of normal

3. Significant renal impairment (serum creatinine > 1.7 mg/dL)

4. Coagulopathy (as evidenced by PT or APTT >1.5 times control in patients not undergoing anticoagulation)

5. Thrombocytopenia (platelet count < 100 x 103/µL)

6. Neutropenia (absolute neutrophil count < 1 x 103/µL)

7. Anemia (Hb < 10 g/L)

8. Severe acute infection

- Implanted pacemaker, defibrillator or deep brain stimulator, or documented clinically significant arrhythmias.

- Infra-tentorial tumor

- Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
NovoTTF-100A
multiple four-week courses of continuous NovoTTF-100A treatment

Locations

Country Name City State
Austria University Hospital Graz Graz
Czech Republic FN Brno - Masaryk University Brno
Czech Republic Na Homolce Hospital Prague
France Hospital of Neurology Lyon - University Claude Bernard Lyon 1 Lyon
France Group Hospitals Pitie-Salpetriere Paris
Germany University Hospital Augsburg Augsburg
Germany University Medical Center Hamburg-Eppendorf Hamburg
Germany University Hospital of Schleswig-Holstein Kiel
Israel Tel Aviv Sourasky Medical Center Tel Aviv
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Boston University Medical Center Boston Massachusetts
United States Lahey Clinic Medical Center Burlington Massachusetts
United States University of Virginia Charlottesville Virginia
United States Northwestern University Chicago Illinois
United States University of Illinois in Chicago Chicago Illinois
United States Cleveland Clinic Cleveland Ohio
United States University Hospitals of Cleveland Cleveland Ohio
United States NJ Neuroscience Institute - JFK Medical Center Edison New Jersey
United States Evanston Northwestern Healthcare Evanston Illinois
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Columbia University Medical Center New York New York
United States Memorial Sloan Kettering Cancer Center New York New York
United States Weill Cornell Medical College New York New York
United States University of Pittsburgh Medical Center (UPMC) Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
NovoCure Ltd.

Countries where clinical trial is conducted

United States,  Austria,  Czech Republic,  France,  Germany,  Israel,  Switzerland, 

References & Publications (3)

Kirson ED, Dbalý V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10152-7. Epub 2007 Jun 5. — View Citation

Kirson ED, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, Schatzberger R, Palti Y. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004 May 1;64(9):3288-95. — View Citation

Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie. 2008 Jul;31(7):362-5. doi: 10.1159/000137713. Epub 2008 Jun 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Survival 2 years from initiation of accrual No
Secondary Progression free survival at 6 months (PFS6) 2 years from initiation of accrual No
Secondary Median Time to Disease Progression (TTP) 2 years from initiation of accrual No
Secondary % 1-year survival 2 years from initiation of accrual No
Secondary Radiological response (Macdonald criteria) 2 years from initiation of accrual No
Secondary Quality of life assessment (EORTC QLQ-C30) 2 years from initiation of accrual No
Secondary Adverse events severity and frequency 2 years from initiation of accrual Yes
See also
  Status Clinical Trial Phase
Completed NCT00597493 - Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Phase 2
Recruiting NCT01737346 - Procarbazine and Lomustine in Recurrent Glioblastoma Phase 2
Active, not recruiting NCT01464177 - Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00562419 - CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Phase 2
Completed NCT00071539 - Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors Phase 2
Active, not recruiting NCT02062827 - Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma Phase 1
Completed NCT00509301 - Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme Phase 1
Recruiting NCT05868083 - The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma Phase 1
Completed NCT01576666 - Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01738646 - Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Phase 2
Completed NCT00306618 - Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma Phase 2
Completed NCT01934361 - Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Phase 1
Terminated NCT04915404 - Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Phase 1/Phase 2
Terminated NCT01756729 - Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Phase 4
Completed NCT00747253 - Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors Phase 1
Completed NCT00883298 - Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00481455 - Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) Phase 2
Recruiting NCT03423628 - A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Phase 1
Recruiting NCT04689087 - A Prospective, Open-label, Single-arm Clinical Study N/A